CEO.CA's Inside the Boardroom: Major U.S. Cancer Centers Are Testing This New Drug: Kairos PharmaNewsfile Corp · 3 days ago
Kairos Pharma Targets Drug Resistance Mechanism Against Prostate CancerBenzinga · Oct 6, 2026
Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate CancerBusiness Wire · Oct 6, 2026
Kairos Pharma to Present and Moderate at Discovery on Target Conference in Boston, MABusiness Wire · Sep 23, 2026
Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceBusiness Wire · Sep 9, 2026
Kairos Pharma Announces 1-for-7 Reverse Stock SplitBusiness Wire · Aug 21, 2026Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for individuals battling cancer. Its therapeutic portfolio includes a range of antibodies and small molecules engineered to combat various malignancies, such as prostate, lung, and breast cancer, as well as glioblastoma. Initially incorporated in 2013 under the name NanoGB13, Inc., the enterprise officially adopted its current identity as Kairos Pharma, Ltd. in July 2016.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 12, 2026 | -$0.63 | -$0.42 | Beat |
| May 13, 2026 | -$0.07 | -$0.08 | Miss |
| Apr 21, 2026 | -$0.84 | -$0.07 | Beat |
| Nov 13, 2025 | -$0.70 | -$0.49 | Beat |
| Aug 13, 2025 | -$0.42 | -$0.08 | Beat |
| Apr 15, 2025 | -$0.05 | -$0.08 | Miss |